AI excels at synthesizing existing knowledge, but drug discovery requires creating new knowledge. Humans have mapped only 10–20% of human biology, so AI models trained on that incomplete dataset produce poor predictions. Meaningful AI acceleration in pharma R&D is a 10-year arc, not a 2-year one.